Up­dat­ed: Take­da’s Ovid-li­censed drug fails two Phase 3 epilep­sy stud­ies

Take­da’s en­zyme ther­a­py soti­cle­stat, which aims to bal­ance brain cho­les­terol and re­duce seizures, failed two Phase 3 tri­als in cer­tain forms …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.